You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 44 No. 4, April 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Correlation of Clinical and Immunologic States in Multiple Sclerosis

M. Ray Mickey, PhD; George W. Ellison, MD; John L. Fahey, MD; Dewey J. Moody, PhD; Lawrence W. Myers, MD

Arch Neurol. 1987;44(4):371-375.


Abstract

• Cyclophosphamide was administered to 14 patients with chronic progressive multiple sclerosis on an intermittent escalating dosage schedule adjusted to maintain numbers of peripheral blood B lymphocytes and helper/inducer (CD4) T cells below the fifth percentile of the normal population. Peripheral blood B cells, T cells, suppressor/cytotoxic (CD8) T cells, CD4 cells, and FcR+-bearing cell numbers and percentages were monitored at one-week to two-week intervals. Clinical status was assessed by neurologic examinations at approximately four-week intervals. Regression analysis revealed a statistically significant correlation between changes in immunologic status and changes in clinical state. The immunologic changes preceded the neurologic changes. Increases in percent of CD8 cells and decreases in percent of CD4 cells forecast improved clinical course. These findings, coupled with other studies, strongly suggest a pathogenetic role for helper and suppressor T cells in the production of clinical signs of multiple sclerosis.



Author Affiliations

From the Department of Biomathematics (Dr Mickey), the Department of Neurology, Reed Neurological Research Center (Drs Ellison and Myers), and the Medical Immunology Laboratory, CIRID, Department of Microbiology and Immunology (Drs Fahey and Moody), UCLA School of Medicine.


Footnotes

Accepted for publication Jan 9, 1987.

Reprint requests to the Department of Neurology, UCLA School of Medicine, Reed Neurological Research Center, 710 Westwood Plaza, Los Angeles, CA 90024 (Dr Myers).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Weiner and Cohen
Mult Scler 2002;8:142-154.
ABSTRACT  

Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol et al.
Mult Scler 1999;5:403-409.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.